Ju­lian Adams jumps ship from a deeply trou­bled In­fin­i­ty Phar­ma

Ju­lian Adams, the R&D chief of In­fin­i­ty Phar­ma­ceu­ti­cals $IN­FI for the past 14 years and a promi­nent face for one of the most high-pro­file biotechs in Cam­bridge, MA, is out.

Like many such an­nounce­ments, In­fin­i­ty cast the de­par­ture as a re­tire­ment, though it’s un­like­ly that Adams is hang­ing up his lab coat. His last day at In­fin­i­ty is to­mor­row, just days af­ter he qual­i­fied for the first pay­ment of a planned $249,000 re­ten­tion bonus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.